BioCentury
ARTICLE | Clinical News

EC approves label expansion for Bial-Portela's epilepsy drug Zebinix

July 28, 2017 6:12 AM UTC

In May, the European Commission approved a label expansion for Zebinix eslicarbazepine acetate (Aptiom - U.S.) (BIA 2-093, SEP-0002093) from Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) to include its use as monotherapy to treat partial-onset seizures, with or without secondary generalization, in adults with newly diagnosed epilepsy...